Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease

Vertex Pharmaceuticals reported positive Phase III results for povetacicept, showing a 52% reduction in proteinuria in kidney disease patients. The drug's safety profile was similar to placebo. Vertex also discussed inaxaplin's potential in treating APOL1-mediated kidney disease, with Phase III AMPLITUDE trial results expected early next year. The company is engaging with payers for povetacicept's commercial coverage.

Novartis' remibrutinib showed 31.2% to 35.2% lower annualized relapse rates vs. teriflunomide in two late-stage MS trials. Both trials met primary endpoints. Novartis plans global regulatory filings. Analysts estimate potential peak sales over $4B, though not company guidance.

Cumberland Pharmaceuticals (CPIX) reported Phase 2a trial results for ifetroban in systemic sclerosis, showing safety and tolerability but no efficacy conclusions. Shares fell 17.55% in after-hours trading. The 12-month trial enrolled 41 patients, with most experiencing limited disease progression. Cumberland plans further studies to guide future development.

Amazon and Google signed 20-year deals with Constellation Energy for nuclear power, totaling $4.3B. Amazon secured 690 MW from Calvert Cliffs, while Google's deal covers 11 reactors. Critics question if these agreements will meet data center demand and impact household electricity costs. The Energy Department approved $4.4B in loans for nuclear facilities. Meta, Microsoft, and Amazon have also made significant nuclear power agreements.

Boeing (NYSE:BA) halted 777 freighter production for two months due to a supplier dispute with Vaero, costing up to $6.5M daily. The issue also impacted 767 aircraft production. Boeing is bringing manufacturing in-house and has removed two partially assembled 777 freighters from its assembly line. The 777X program is unaffected. Boeing has delivered 21 777 freighters this year, with more possible by 2026.

Moderna and Merck reported late-stage trial results showing their personalized mRNA melanoma vaccine, intismeran, reduced relapse risk by 42% when combined with Keytruda. The trial involved 1,137 patients, with 82% of vaccine recipients showing no recurrence after two years, compared to 70% for the placebo group. The companies plan to present the findings at a medical conference and continue long-term studies.